To clarify the interaction between hepatitis B virus (HBV) infection and lipid metabolism, and to investigate whether regulation of fatty acid metabolism can alleviate mitochondrial dysfunction caused by HBV infection.
Key Findings:
HBV infection leads to fatty acid β-oxidation disorder and mitochondrial dysfunction.
CPT1A overexpression improves mitochondrial function in hepatocytes, particularly in the context of HBV infection.
Decanoylcarnitine stimulates the PPAR signaling pathway, particularly PPARα.
Interpretation:
Exogenous supplementation of decanoylcarnitine can partially restore impaired fatty acid metabolism and mitochondrial dysfunction in hepatocytes caused by HBV infection, indicating its potential as a therapeutic agent.
Limitations:
The study primarily focuses on mouse models and cell lines, which may not fully replicate human responses, limiting the generalizability of the findings.
Further clinical studies are needed to validate the findings in human subjects.
Conclusion:
Decanoylcarnitine shows promise as a therapeutic agent for improving mitochondrial dysfunction and fatty acid metabolism in HBV-infected liver cells.
